Serimmune Inc.

Serimmune Inc. is an immunology research company focused on innovative epitope profiling and discovery technologies that enhance understanding of immune responses to pathogens, aiming to advance therapeutic and vaccine development. Founded in 2014 in Goleta, US, Serimmune specializes in immunology research through its unique profiling platform. The company has engaged in two deals, with its most recent financing round occurring on May 22, 2019.

In this round, Serimmune raised USD 1. 41 mn in Venture Debt, contributing to a total funding of USD 8. 00 mn. The founder's previous entrepreneurial experience is not specified.

Serimmune specializes in immunology research, primarily through its innovative short epitope profiling and discovery platform. This technology allows for the identification and characterization of specific immune responses to pathogens, enabling researchers to understand the complexities of human immunity more effectively. The company’s integration with Infinity Bio enhances its offerings by incorporating advanced methodologies that utilize rationally designed peptides and full-length proteins, which are crucial for antibody development and therapeutic applications. Serimmune serves a diverse clientele that includes pharmaceutical companies, biotechnology firms, and academic research institutions, focusing on markets in North America, Europe, and parts of Asia.

The goal of these products and services is to facilitate the development of targeted therapies and vaccines, ultimately improving patient outcomes in immunologic diseases. Serimmune generates revenue through partnerships and collaborations with various stakeholders in the life sciences sector, including pharmaceutical and biotechnology companies. The company’s business model is structured around B2B transactions, where clients access its proprietary epitope profiling services and advanced immunological tools under contractual agreements. Revenue streams may include project-based fees for specific research initiatives, along with potential ongoing royalties from developed therapies that leverage Serimmune’s technology.

Additionally, the company may offer subscription-based access to its platform for continuous research needs from clients engaged in long-term studies. While specific pricing plans for its products and services are not disclosed, the firm’s focus on delivering cutting-edge solutions positions it favorably within the competitive landscape of immunology research. With the recent Venture Debt financing on May 22, 2019, Serimmune plans to enhance its research capabilities and expand its product offerings. The company aims to introduce new products that enhance its epitope profiling technology in the upcoming years.

Furthermore, Serimmune is targeting expansion into new geographic markets, including increased presence in Europe and parts of Asia by 2025. The funding will primarily be utilized to support the development of these innovative products and to facilitate entry into these new markets.